Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
9.00
Dollar change
+0.80
Percentage change
9.76
%
Index- P/E- EPS (ttm)-13.43 Insider Own9.48% Shs Outstand2.95M Perf Week13.07%
Market Cap26.64M Forward P/E- EPS next Y-11.22 Insider Trans0.00% Shs Float2.68M Perf Month-4.87%
Income-39.48M PEG- EPS next Q-3.09 Inst Own14.98% Short Float0.56% Perf Quarter-19.24%
Sales0.79M P/S33.72 EPS this Y10.42% Inst Trans-73.01% Short Ratio1.05 Perf Half Y45.16%
Book/sh10.19 P/B0.88 EPS next Y6.69% ROA-74.93% Short Interest0.02M Perf Year-41.69%
Cash/sh11.57 P/C0.78 EPS next 5Y0.00% ROE-86.75% 52W Range5.22 - 16.60 Perf YTD-16.08%
Dividend Est.- P/FCF- EPS past 5Y18.19% ROI-130.74% 52W High-45.78% Beta1.16
Dividend TTM- Quick Ratio6.94 Sales past 5Y-9.91% Gross Margin72.08% 52W Low72.41% ATR (14)0.58
Dividend Ex-Date- Current Ratio6.94 EPS Y/Y TTM20.19% Oper. Margin-5313.89% RSI (14)53.55 Volatility5.90% 6.66%
Employees27 Debt/Eq0.01 Sales Y/Y TTM-47.32% Profit Margin-5029.17% Recom1.50 Target Price31.33
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q22.86% Payout- Rel Volume1.02 Prev Close8.20
Sales Surprise132.03% EPS Surprise-0.81% Sales Q/Q73.68% EarningsMar 07 AMC Avg Volume14.23K Price9.00
SMA202.43% SMA500.92% SMA20018.00% Trades Volume14,521 Change9.76%
Date Action Analyst Rating Change Price Target Change
Apr-07-21Initiated Oppenheimer Outperform $14
Feb-23-21Initiated Northland Capital Outperform $21
Mar-15-24 09:00AM
Mar-08-24 10:26AM
Mar-07-24 09:54PM
04:01PM
Feb-29-24 04:05PM
04:30PM Loading…
Feb-06-24 04:30PM
Feb-01-24 09:00AM
Jan-08-24 09:00AM
Jan-04-24 09:00AM
Jan-02-24 09:00AM
Dec-28-23 11:04AM
Dec-26-23 09:00AM
Nov-11-23 11:06AM
Nov-09-23 04:01PM
Nov-02-23 04:05PM
09:00AM Loading…
Oct-26-23 09:00AM
Oct-25-23 09:00AM
Oct-05-23 04:01PM
Sep-07-23 09:00AM
Aug-10-23 04:01PM
Aug-03-23 04:30PM
04:05PM
Jul-26-23 01:30PM
Jun-30-23 04:30PM
Jun-06-23 04:01PM
May-31-23 05:00PM
May-06-23 08:14AM
May-04-23 04:01PM
Apr-27-23 05:00PM
Apr-17-23 06:54AM
05:00PM Loading…
Apr-13-23 05:00PM
Apr-03-23 04:01PM
Mar-27-23 09:00AM
Mar-11-23 03:14AM
Mar-09-23 04:01PM
Mar-02-23 05:00PM
Mar-01-23 05:00PM
Feb-01-23 05:00PM
Jan-04-23 04:05PM
Jan-03-23 05:00PM
Dec-10-22 03:00PM
Dec-01-22 05:00PM
Nov-14-22 05:00PM
Nov-03-22 04:01PM
09:05AM
Oct-27-22 05:53PM
Oct-03-22 05:30PM
04:31PM
Sep-27-22 09:00AM
Sep-23-22 09:00AM
Sep-07-22 05:00PM
Aug-09-22 04:05PM
Aug-02-22 05:00PM
Jul-26-22 07:34AM
Jul-14-22 04:01PM
Jun-10-22 04:30PM
09:00AM
Jun-02-22 09:00AM
Jun-01-22 05:00PM
May-26-22 05:15PM
May-17-22 07:40AM
May-05-22 04:01PM
May-02-22 05:00PM
Apr-28-22 05:00PM
03:02PM
Apr-13-22 08:30AM
Apr-01-22 05:00PM
Mar-10-22 04:01PM
Mar-07-22 05:00PM
Mar-01-22 05:00PM
Feb-16-22 10:11AM
Jan-20-22 04:05PM
Jan-19-22 05:38PM
Jan-04-22 04:01PM
Dec-14-21 08:53AM
Dec-13-21 08:00AM
Dec-01-21 05:00PM
Nov-15-21 08:00AM
Nov-09-21 05:00PM
Nov-04-21 04:05PM
Nov-03-21 05:00PM
Nov-02-21 05:00PM
Nov-01-21 04:05PM
Oct-29-21 08:00AM
Oct-27-21 03:03PM
Oct-15-21 10:51AM
Oct-05-21 04:05PM
Oct-01-21 04:01PM
Sep-20-21 08:00AM
08:00AM
Sep-09-21 04:01PM
Sep-01-21 04:01PM
Aug-16-21 01:17PM
Aug-05-21 04:01PM
Aug-02-21 04:05PM
04:04PM
Jul-29-21 03:05PM
08:00AM
Jul-01-21 04:05PM
Jun-01-21 04:05PM
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HALE DAVID FDirectorFeb 23 '24Buy9.047146,455714Feb 27 05:03 PM
HALE DAVID FDirectorFeb 23 '24Buy9.042662,40529,673Feb 27 05:03 PM
Wills Robert JamesDirectorFeb 23 '24Sale9.049808,8590Feb 27 05:02 PM
Kaufmann Gunnar F.Chief Scientific OfficerJun 14 '23Buy0.363,0001,07994,726Jun 14 04:00 PM
Kaufmann Gunnar F.Chief Scientific OfficerJun 12 '23Buy0.3525,0008,74591,726Jun 14 04:00 PM
BREITMEYER JAMES BChief Executive OfficerApr 14 '23Buy0.3050,00014,930196,544Apr 17 06:00 AM
Yazji SalimChief Medical OfficerApr 14 '23Buy0.305,0001,500164,676Apr 14 06:02 PM
BREITMEYER JAMES BChief Executive OfficerApr 13 '23Buy0.29100,00029,000146,544Apr 17 06:00 AM
VINCENT RICHARD GChief Financial OfficerApr 13 '23Buy0.3030,0008,961156,859Apr 14 06:00 AM
Leavitt Chase C.General Counsel/SecretaryApr 13 '23Buy0.2910,0002,900106,901Apr 14 06:00 AM
Yazji SalimChief Medical OfficerApr 13 '23Buy0.2810,0002,850159,676Apr 14 06:02 PM
Leavitt Chase C.General Counsel/SecretaryApr 12 '23Buy0.2915,0004,35096,901Apr 14 06:00 AM
Yazji SalimChief Medical OfficerApr 12 '23Buy0.2810,0002,850149,676Apr 14 06:02 PM